Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FRANCIS cardiovascular risk reduction study in rheumatoid arthritis
NL-OMON23703Phase 3Active, not recruiting
- Sponsor
- Franciscus Gasthuis & Vlietland
- Start
- Feb 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of perindopril, indapamide, simvastatin, atorvastatin, fluvastatin and 3 more in atherosclerosis and rheumatoid arthritis (RA) (3 arms), sponsored by Franciscus Gasthuis & Vlietland. Primary endpoint: Progression of carotid artery intima-media thickness. Started Feb 2011; status: active, not recruiting.
02
Drugs
perindoprilindapamidesimvastatinatorvastatinfluvastatin
03
Conditions
atherosclerosisrheumatoid arthritis (RA)
Beyond the preview
Go deeper on NL-OMON23703.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON23703.